Valuation: AbbVie Inc.

Market Cap 466B 407B 384B 349B 653B 44,758B 656B 4,600B 1,775B 22,756B 1,752B 1,713B 73,219B P/E 2026 *
33.4x
P/E 2027 * 24.9x
Enterprise Value 528B 460B 435B 395B 740B 50,668B 743B 5,208B 2,010B 25,760B 1,984B 1,940B 82,887B EV / Sales 2026 *
7.81x
EV / Sales 2027 * 7.07x
Free-Float
95.71%
Yield 2026 *
2.6%
Yield 2027 * 2.73%
1 day+1.54%
1 week+4.42%
Current month+5.52%
1 month+4.00%
3 months+20.84%
6 months+27.14%
Current year+18.67%
1 week 221.2
Extreme 221.2
232.4
1 month 212.8
Extreme 212.8
232.4
Current year 167.55
Extreme 167.55
234.4
1 year 167.55
Extreme 167.55
234.4
3 years 125.5
Extreme 125.5
234.4
5 years 90.5
Extreme 90.5
234.4
10 years 50.18
Extreme 50.183
234.4
Manager TitleAgeSince
Chief Executive Officer 55 2024-06-30
Director of Finance/CFO 59 2022-06-22
Chief Tech/Sci/R&D Officer - 2024-02-29
Director TitleAgeSince
Director/Board Member 65 2012-12-31
Director/Board Member 74 2012-12-31
Director/Board Member 69 2012-12-31
Change 5-day change 1-year change 3-year change Capi.($)
+1.54%+4.42% - - 466B
+0.04%+3.34%+51.12%+101.82% 1,028B
-0.09%+1.66%+55.02%+66.18% 651B
-0.02%+2.66%+18.91%+71.47% 466B
-1.22%+3.66%+36.44%+38.32% 346B
-0.79%+2.73%+19.03%+25.08% 266B
+0.58%+6.76%+11.13%+16.52% 259B
+1.55%+2.20%+39.81%+46.55% 208B
+0.79%+1.84%-28.27%-56.71% 191B
-0.52%+4.45%+32.12%+98.51% 186B
Average +0.34%+3.26%+26.15%+45.30% 400.19B
Weighted average by Cap. +0.38%+3.09%+35.15%+61.76%

Financials

2026 *2027 *
Net sales 67.59B 58.94B 55.65B 50.53B 94.68B 6,485B 95.08B 667B 257B 3,297B 254B 248B 10,609B 73.49B 64.08B 60.51B 54.95B 103B 7,052B 103B 725B 280B 3,585B 276B 270B 11,536B
Net income 14.08B 12.28B 11.59B 10.53B 19.72B 1,351B 19.81B 139B 53.59B 687B 52.89B 51.71B 2,210B 19.09B 16.64B 15.72B 14.27B 26.74B 1,832B 26.85B 188B 72.65B 931B 71.7B 70.11B 2,996B
Net Debt 61.59B 53.71B 50.71B 46.05B 86.28B 5,910B 86.64B 607B 234B 3,005B 231B 226B 9,668B 53.09B 46.3B 43.71B 39.7B 74.37B 5,094B 74.68B 524B 202B 2,590B 199B 195B 8,334B
Logo AbbVie Inc.
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (76.2%), Germany (2.8%), Japan (2.1%), Canada (2%), China (1.6%), France (1.3%), the United Kingdom (1%), Spain (1%), Italy (0.9%), Brazil (0.8%), Australia (0.8%), and Other (9.5%).
Employees
57,000
Date Price Change Volume
26-09-18 €231.40 +1.54% 22
26-09-17 €227.90 +0.57% 0
26-09-16 €226.60 -0.31% 3
26-09-15 €227.30 +0.35% 15
26-09-14 €226.50 +2.21% 10
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
30
Last Close Price
263.96USD
Average target price
278.61USD
Spread / Average Target
+5.55%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!